Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study - Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet ...
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
Potential biomarkers in nab-paclitaxel/gemcitabine (a), Folfirinox (b)... | Download Scientific Diagram
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Semantic Scholar
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
Gemcitabine Plus Nab-paclitaxel As A Second-line Treatment, 56% OFF
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study | British Journal of Cancer
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect
Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram
Nab-paclitaxel (Abraxane®) - Pancreatic Cancer UK
![PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a8478459bead2b5ce4b12ab3728c7bfce9ce856a/4-Figure3-1.png "PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar")
PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar
Nab-Paclitaxel + Gem/Cis for BTCs - Slideset Download - ASCO GI 2023 | CCO
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
GI Chemotherapy Education – GA/GemNab: Gemcitabine and Nab-paclitaxel (Abraxane®) - YouTube
Design of study protocol | Download Scientific Diagram
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Nab-paclitaxel/gemcitabine combo boosts OS in resected pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
